ATL-001

About Atlas Molecular Pharma

Atlas Molecular Pharma is a private, preclinical-stage biotech based in Derio, Spain, targeting rare diseases with a proprietary platform called Chassys™. The platform leverages NMR-based technology to design pharmacological chaperones that stabilize misfolded proteins, a common pathogenic mechanism in many rare genetic disorders. The company's lead program, ATL-001, targets Congenital Erythropoietic Porphyria (CEP), and it operates on a capital-efficient, asset-centric licensing model. As a pre-revenue entity, its success hinges on advancing its pipeline through preclinical validation to secure lucrative licensing deals with larger pharmaceutical partners.

Therapeutic Areas